Form 4: Amphastar Director Howard Lee Reports Equity Transactions

Director Howard Lee acquired restricted stock units and stock options while disposing of shares to cover tax obligations.

Summary

• Director Howard Lee received 8,143 restricted stock units (RSUs) on June 1, 2026, vesting on June 1, 2027.
• Director Howard Lee was granted 17,365 stock options with an exercise price of $18.42, vesting on June 1, 2027.
• A total of 769 shares were withheld on June 2, 2026, at a price of $18.45 to satisfy tax liabilities related to RSU vesting.
• Following these transactions, the reporting person holds 159,350 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director equity compensation.

Positives

• Director alignment with long-term company performance through equity-based compensation.
• Standard tax withholding procedure indicates routine management of equity awards.

Negatives

• Minor reduction in total share count due to tax withholding requirements.

Risks

• Market price volatility affecting the value of equity-based compensation.
• Vesting conditions tied to future dates create dependency on continued service.

Future Outlook

The equity grants vest in full on June 1, 2027, aligning the director's interests with the company's performance over the next year.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common in the pharmaceutical sector to ensure board members maintain a significant equity stake in the issuer.

Comparison to Industry Standards

• The use of RSUs and stock options as director compensation is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
• Tax withholding via share reduction is a standard industry practice for settling tax obligations upon the vesting of equity awards.

Stakeholder Impact

• Minimal impact on shareholders as these are standard compensation-related transactions.

Next Steps

• Vesting of RSUs and stock options on June 1, 2027.

Key Dates

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Equity Compensation, Director Transactions